Form 4: Apogee Therapeutics Director Jennifer Fox Granted Stock Options

Apogee Therapeutics, Inc. Director Jennifer A. Fox was granted 14,461 stock options with an exercise price of $41.66, vesting over one year.

Summary

• Jennifer A. Fox, a Director of Apogee Therapeutics, Inc. (APGE), was granted stock options.
• The grant date for these options was June 17, 2025.
• The options allow the purchase of 14,461 shares of Apogee Therapeutics common stock.
• The exercise price for these options is $41.66 per share.
• The options will vest on the one-year anniversary of the grant date, which is June 17, 2026, contingent on Ms. Fox's continued service to the company.
• The options have an expiration date of June 17, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice that aligns management's interests with shareholders, indicating a routine compensation event with a positive implication for governance alignment.

Positives

• The grant of stock options to Director Jennifer A. Fox aligns her interests with those of shareholders, incentivizing long-term performance and value creation for Apogee Therapeutics.

Risks

• The vesting of the stock options is subject to the reporting person's continued service to the Issuer; if service ceases before the vesting date of June 17, 2026, the unvested options could be forfeited.

Future Outlook

The stock options granted to Director Jennifer A. Fox are scheduled to vest on the one-year anniversary of the grant date, June 17, 2026, contingent upon her continued service to Apogee Therapeutics, Inc.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation designed to align the interests of board members with those of shareholders. This practice aims to encourage directors to contribute to the company's sustained growth and value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology. While specific grant sizes and vesting schedules vary, the use of equity-based incentives like stock options is a widely accepted mechanism to attract and retain qualified board members and align their financial interests with long-term shareholder value. Without specific comparable companies or projects mentioned, a direct quantitative comparison is not feasible from this document alone.

Related Party Transactions

• The grant of stock options to Jennifer A. Fox, a Director of Apogee Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's long-term financial interests with those of the shareholders, potentially leading to improved governance and strategic decisions aimed at increasing shareholder value.

Next Steps

• The stock options will vest on June 17, 2026, subject to Jennifer A. Fox's continued service to Apogee Therapeutics, Inc.

Key Dates

Keywords

Apogee Therapeutics, APGE, Stock Option Grant, Form 4, Insider Transaction, Director Compensation, Equity Compensation